(Korean) 보로노이, 美 바이오社에 6680억 기술 수출- 한국경제 BIO Insight
admin2022-12-01T14:26:54+00:00Sorry, this entry is only available in Korean.
Sorry, this entry is only available in Korean.
Sorry, this entry is only available in Korean.
Sorry, this entry is only available in Korean.
JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field - mk.co.kr On December 2, JW Pharmaceutical inked a deal with Korean biotech startup Voronoi to develop next-generation innovative new drugs. It plans to develop a next-generation innovative new drug with global competitiveness by combining JW Pharmaceutical's small molecule anticancer drug candidate of targeting STAT3 with Voronoi's protein decomposition technology 'Protein Degrader(PROTAC; Proteolysis-targeting chimera)'. 기사 전문보기
Sorry, this entry is only available in Korean.
Sorry, this entry is only available in Korean.
Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi-AsiaBiz View the update
Dana-Farber Cancer Institute and Deerfield Management announced today an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber to be led by BCMP Faculty members, Nathanael Gray and Eric Fischer,.
미국 암학회 대표, 한국 벤처 극찬..폐암 치료제 호평 - 헤럴드경제 암학회(AACR) 대표 마가렛 포티 박사 트위터로 한국기업 보로노이 발표 올리며 "큰 관심 쏟아져" "복수의 글로벌사와 기술수출 협의 중" 대박 기대감 기사 전문보기